- € 38.7 Mio. German government funding for the clinical development of a Corona medication
- CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE
- CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant
- CORAT Therapeutics secures additional funding for Phase II clinical evaluation of its COVID-19 treatment
- TV report on COR-101
No comments to show.